Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 12Terminated 3Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Osteosarcoma 2Neuroblastoma 2Lymphoma 2Leukemia 2Colonic Neoplasms 2Xanthomatosis, Cerebrotendinous 1Unspecified Adult Solid Tumor, Protocol Specific 1Tetanus 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Docetaxel 56Prednisone 36enzalutamide 25Leuprolide 24Magnetic Resonance Spectroscopy 19Abiraterone Acetate 19bicalutamide 17Radiotherapy 15Goserelin 15abiraterone 12acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11olaparib 9Androgen Antagonists 9gallium 68 PSMA-11 8cabazitaxel 8Radiotherapy, Intensity-Modulated 8Metformin 8Ketoconazole 8Gonadotropin-Releasing Hormone 8Cyclophosphamide 8apalutamide 7Doxorubicin 7luprolide acetate gel depot 6cabozantinib 6Radiosurgery 6Estramustine 6Dexamethasone 6Calcitriol 6Biopsy 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT00477087 2017-11-29

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Stanford University

Phase 2 Terminated
10 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00447473 2016-03-17

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Terminated
31 enrolled
Genitourinary

Prostatic Neoplasms

NCT00450008 2016-03-17

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Terminated
9 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡